These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

687 related items for PubMed ID: 21728914

  • 1. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
    Baser O, Andrews LM, Wang L, Xie L.
    J Med Econ; 2011; 14(5):576-83. PubMed ID: 21728914
    [Abstract] [Full Text] [Related]

  • 2. Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy.
    Malesker MA, Hilleman DE.
    Manag Care; 2010 Jul; 19(7):36-42. PubMed ID: 20672530
    [Abstract] [Full Text] [Related]

  • 3. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
    Frampton JE, Scott LJ.
    Am J Cardiovasc Drugs; 2009 Jul; 9(5):309-30. PubMed ID: 19791840
    [Abstract] [Full Text] [Related]

  • 4. Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
    Hussein MA, Chapman RH, Benner JS, Tang SS, Solomon HA, Joyce A, Foody JM.
    Am J Cardiovasc Drugs; 2010 Jul; 10(3):193-202. PubMed ID: 20387911
    [Abstract] [Full Text] [Related]

  • 5. Adherence and persistence of single-pill ARB/CCB combination therapy compared to multiple-pill ARB/CCB regimens.
    Zeng F, Patel BV, Andrews L, Frech-Tamas F, Rudolph AE.
    Curr Med Res Opin; 2010 Dec; 26(12):2877-87. PubMed ID: 21067459
    [Abstract] [Full Text] [Related]

  • 6. Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.
    Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH.
    Curr Med Res Opin; 2010 Apr; 26(4):849-60. PubMed ID: 20141381
    [Abstract] [Full Text] [Related]

  • 7. Antihypertensive therapy with CCB/ARB combination in older individuals: focus on amlodipine/valsartan combination.
    Kostis JB.
    Am J Ther; 2010 Apr; 17(2):188-96. PubMed ID: 19433970
    [Abstract] [Full Text] [Related]

  • 8. Comparison of amlodipine/valsartan/hydrochlorothiazide single pill combination and free combination: adherence, persistence, healthcare utilization and costs.
    Machnicki G, Ong SH, Chen W, Wei ZJ, Kahler KH.
    Curr Med Res Opin; 2015 Dec; 31(12):2287-96. PubMed ID: 26397178
    [Abstract] [Full Text] [Related]

  • 9. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R.
    Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280
    [Abstract] [Full Text] [Related]

  • 10. Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database.
    Jackson KC, Sheng X, Nelson RE, Keskinaslan A, Brixner DI.
    Clin Ther; 2008 Aug; 30(8):1558-63. PubMed ID: 18803997
    [Abstract] [Full Text] [Related]

  • 11. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C, Croce G, Desideri G.
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [Abstract] [Full Text] [Related]

  • 12. Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan.
    Tung YC, Lin YS, Wu LS, Chang CJ, Chu PH.
    J Clin Hypertens (Greenwich); 2015 Jan; 17(1):51-8. PubMed ID: 25477188
    [Abstract] [Full Text] [Related]

  • 13. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study.
    Saito I, Saruta T, ADVANCE-Combi Study Group.
    Hypertens Res; 2006 Oct; 29(10):789-96. PubMed ID: 17283866
    [Abstract] [Full Text] [Related]

  • 14. Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations.
    Ferrario CM, Panjabi S, Buzinec P, Swindle JP.
    Ther Adv Cardiovasc Dis; 2013 Feb; 7(1):27-39. PubMed ID: 23328188
    [Abstract] [Full Text] [Related]

  • 15. Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension.
    Kumagai N, Onishi K, Hoshino K, Nakamori S, Kitai T, Yazu T, Oota M, Ueda Y, Hiraoka N, Okamoto S, Yamada T, Dohi K, Nakamura M, Ito M.
    Clin Exp Hypertens; 2013 Feb; 35(5):355-60. PubMed ID: 23072348
    [Abstract] [Full Text] [Related]

  • 16. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
    Brachmann J, Ansari A, Mahla G, Handrock R, Klebs S.
    Adv Ther; 2008 May; 25(5):399-411. PubMed ID: 18465097
    [Abstract] [Full Text] [Related]

  • 17. Single-pill combination of amlodipine and valsartan in the management of hypertension.
    Flack JM, Hilkert R.
    Expert Opin Pharmacother; 2009 Aug; 10(12):1979-94. PubMed ID: 19606937
    [Abstract] [Full Text] [Related]

  • 18. Long-term clinical and economic outcomes associated with angiotensin II receptor blocker use in hypertensive patients.
    Swindle JP, Buzinec P, Iorga SR, Ramaswamy K, Panjabi S.
    Curr Med Res Opin; 2011 Sep; 27(9):1719-31. PubMed ID: 21767101
    [Abstract] [Full Text] [Related]

  • 19. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine.
    Weycker D, Edelsberg J, Vincze G, Kjeldsen SE, Jamerson K, Khan ZM, Oster G.
    J Hum Hypertens; 2007 May; 21(5):374-80. PubMed ID: 17314999
    [Abstract] [Full Text] [Related]

  • 20. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA.
    Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.